Onconova Therapeutics (NASDAQ: ONTX) was downgraded by Zacks.com  from a “buy” rating to a “hold” rating in a research note issued to capitalists on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical firm. It focuses on finding and also developing little molecule drug candidates to deal with cancer cells. The Company‘s items under different phases of growth consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research analysts also recently commented on the firm. Noble Financial editioned a “purchase” rating and also provided a $11.00 cost purpose on shares of Onconova Therapeutics in a record on Thursday, September 23rd. Guggenheim dropped their rate target on Onconova Therapeutics from $29.00 to $12.00 and also established a “purchase” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened up at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. The business has a 50 day relocating average price of $2.90 and also a two-hundred day relocating average price of $4.16. The firm has a market cap of $46.76 million, a P/E ratio of -1.82 as well as a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly earnings outcomes on Thursday, November 11th. The biopharmaceutical business reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an adverse return on equity of 59.78% as well as an adverse net margin of 8,294.27%. The company had income of $0.06 million throughout the quarter, contrasted to the agreement quote of $0.06 million. Throughout the exact same quarter in the prior year, the company posted ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will certainly upload -1.18 EPS for the existing year.

A number of hedge funds have lately dealt shares of ONTX. GSA Funding Allies LLP bought a new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Capital Monitoring LP purchased a new setting in shares of Onconova Therapeutics in the 3rd quarter worth $635,000. Pura Vida Investments LLC acquired a new position in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC bought a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP acquired a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional capitalists own 13.36% of the company’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which takes part in the identification and also development of oncology therapeutics. It concentrates on finding as well as developing small molecule medicine candidates to treat cancer cells. The company was founded by Ramesh Kumar as well as E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a free duplicate of the Zacks research report on Onconova Therapeutics (ONTX).

For more details regarding research offerings from Zacks Investment Research, browse through Zacks.com.

This immediate information alert was generated by narrative science technology as well as monetary data from Market in order to supply visitors with the fastest and also most accurate coverage. This tale was examined by Market’s content team prior to publication. 

 

SHOULD YOU INVEST $1,000 IN ONCONOVA THERAPEUTICS NOW?

Prior to you take into consideration Onconova Therapeutics, you’ll wish to hear this.

Market keeps an eye on Wall Street’s premier and also ideal performing research analysts and the stocks they advise to their clients each day. Market has recognized the 5 stocks that top experts are quietly murmuring to their clients to acquire now before the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics presently has a “Buy” rating among analysts, premier analysts think these five stocks are much better gets.